tenofovir has been researched along with racivir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carruth, LM; Clements, JE; Li, M; Mankowski, JL; Miller, MD; Queen, LA; Shen, A; Siliciano, RF; Tarwater, PM; Zink, MC | 1 |
| Dandekar, S; Sankaran, S; Verhoeven, D | 1 |
| Amancha, PK; Ansari, AA; Hong, JJ; Rogers, K; Villinger, F | 1 |
3 other study(ies) available for tenofovir and racivir
| Article | Year |
|---|---|
SIV-specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected pigtailed macaques during suppressive combination antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Drug Therapy, Combination; Emtricitabine; Immunity, Cellular; Interferon-gamma; Linear Models; Macaca nemestrina; Organophosphonates; Primate Diseases; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; T-Lymphocytes; Tenofovir; Viremia; Zalcitabine | 2005 |
Simian immunodeficiency virus infection induces severe loss of intestinal central memory T cells which impairs CD4+ T-cell restoration during antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Disease Models, Animal; DNA, Viral; Emtricitabine; Flow Cytometry; Immunologic Memory; Lymphoid Tissue; Macaca mulatta; Organophosphonates; Polymerase Chain Reaction; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; T-Lymphocyte Subsets; Tenofovir; Viral Load; Virus Replication; Zalcitabine | 2007 |
In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antibodies, Monoclonal; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Drug Evaluation, Preclinical; Emtricitabine; Histocompatibility Antigens Class I; Immunity, Cellular; Immunoglobulin Fc Fragments; Immunotherapy; Lymphokines; Macaca mulatta; Organophosphonates; Programmed Cell Death 1 Receptor; Recombinant Proteins; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Solubility; Tenofovir; Viremia; Zalcitabine | 2013 |